Marketing-authorisation holder · United States
Acadia Pharms Inc
5 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
5 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
5 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| DAYBUE200mg/ml · Solution | Trofinetide | United States | Marketed | 2023 |
| DAYBUE STIX10,000mg | 12,000mg · Solution | Trofinetide | United States | Marketed | 2025 |
| DAYBUE STIX5000mg/packet | 6000mg/packet | 8000mg/packet · For solution | Trofinetide | United States | Marketed | 2025 |
| NUPLAZID10MG BASE | 17MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Pimavanserin | United States | Marketed | 2016 |
| NUPLAZID34mg base · Capsule | Pimavanserin | United States | Marketed | 2018 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 5 | 5 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.